Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2022-12-15 00:00:00 ET · period of report 2022-12-13 · accession 0001567619-22-021653 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-15 | 2022-12-13 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale | $106.89 | -1,000 | 320.4K | -0.3% | -$106.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-13 | S | D | 1,000 | $106.89 | 320,424 | D | — | — | (F1) The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $86.1178 on November 2, 2022. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. |